Key Highlights from the Form 8-K Filing

• Company: Protara Therapeutics, Inc. (Nasdaq: TARA)
• Date of Report: March 30, 2026
• Filing Type: Form 8-K (Current Report)
• Subject: Regulation FD Disclosure; update regarding April 2024 Common Warrants
• Trading Symbol: TARA
• Exchange: Nasdaq Global Market
• Company Address: 345 Park Avenue South, 3rd Floor, New York, NY 10010
• Telephone: (646) 844-0337
• Emerging Growth Company: Protara is not classified as an emerging growth company

Important Shareholder Information

• April 2024 Common Warrants Update:
  • The company has announced the termination date for the exercise of the April 2024 Common Warrants.
  • Exercise Price: \$5.25 per share
  • Exercise Period: Warrants may be exercised at any time on or prior to June 29, 2026.
• Potential Price Sensitivity:
  • The update on the exercise period and price for the warrants is material for shareholders and investors. The ability to exercise warrants at \$5.25 per share until June 29, 2026 could directly affect the stock’s supply and demand dynamics, potentially impacting the share price.
  • Investors holding or considering the warrants should be aware of this deadline and price, as approaching expiration or increased exercise activity may lead to share price volatility.
• Regulation FD Disclosure:
  • The information disclosed in Item 7.01 of the Form 8-K is furnished (not filed) and is not subject to Section 18 of the Exchange Act, nor is it incorporated by reference in any other SEC filings unless specifically referenced.
  • This means the information is intended for public dissemination and transparency, but does not trigger additional legal liability under Exchange Act reporting requirements.

Other Noteworthy Details

• Security Information:
  • The company’s main security is Common Stock, par value \$0.001 per share.
  • Trading symbol remains TARA.
  • Listed and traded on the Nasdaq Global Market.
• Corporate Status:
  • Protara Therapeutics, Inc. is not a shell company.
  • The company has previously changed its name from ArTara Therapeutics, Inc. (January 2020) and Proteon Therapeutics Inc. (April 2006).
• No Additional Price-Sensitive Disclosures:
  • There are no disclosures regarding financial results, clinical trial updates, business developments, or material events other than the warrant exercise update.
  • No written communications, soliciting materials, or tender offer communications are included in this filing.

Conclusion and Investor Considerations

The main news from Protara Therapeutics, Inc.’s March 30, 2026 8-K filing is the finalization of the exercise period for the April 2024 Common Warrants. This is a material development for shareholders and market participants, as warrant exercise windows and prices can directly influence share price movements, especially as expiration approaches. Investors should monitor trading activity around the exercise period and assess implications for dilution, supply, and demand in TARA shares.

Disclaimer

This article is based on information provided in Protara Therapeutics, Inc.’s Form 8-K filed on March 30, 2026. It is intended for informational purposes only and should not be construed as financial advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The author does not hold any position in the securities mentioned.